A urate crystal buildup in joints and connective tissue (tophi) is a hallmark of gout, a metabolic condition that may manifest as acute or chronic episodes of arthritis. When it comes to the painful illness known as gout, high levels of serum uric acid (SUA) aren't necessary. Precipitating and depositing in joints, the kidneys, and the subcutaneous bone occurs when blood concentrations of uric acid are high due to the limited water solubility of uric acid. Hyperuricemia is the sole major cause of gout, but the majority of those who have it do not develop gout or even uric acid crystals. Unlike previous vesicular systems, transferosomes are a completely new kind of vesicular system. In addition to the edge activators, phospholipids, ethanol, and sodium cholate, they are administered to the skin in a non-occlusive manner. This project focuses on the two-factor model. Drug entrapment in transferosome vesicles and skin penetration are both improved by this method. Thereafter, the transferosome formulation was made by choosing the best-reported polymer ratio. At three different levels, we've analysed two independent variables. F1 through F9 have been formulated in total. Among the F1-F9 batch, Formulation F4 has shown the most promising outcomes. Entrapment of 89.5 percent was achieved with Formulation F4 and in vitro penetration of 55.56 percent was achieved in 3 hours with Formulation F4. Particles with a diameter of 222 nm were observed. When compared to pure febuxostat gel, the transferosome gel demonstrated greater trapping and skin penetration (56.88 percent) (33.00 percent). A combination of febuxostat and quercetin transferosome gel has been shown to be more effective in reducing gout symptoms than a single febuxostat gel. So, the experiment demonstrates the synergistic impact of including bioactives into the equation